Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)
NCT04032158 · EMD Serono Research & Development Institute, Inc. · PHASE3 · terminated · last registry update 2021-08-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early.” | – | Registry record, EMD Serono Research & Development Institute, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BTK within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-06Results posted on the registry: Acerta Pharma BV, Acalabrutinib + Pembrolizumab (NCT02362035)
- 2022-03-28Results posted on the registry: Janssen Research & Development, LLC, Ibrutinib + Venetoclax (NCT03462719)
- 2022-02-24Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Ibrutinib (NCT05254743)
- 2022-02-18Results posted on the registry: Pharmacyclics LLC., ibrutinib + venetoclax (NCT02910583)
- 2022-02-09Results posted on the registry: Acerta Pharma BV, ACP-196 (acalabrutinib) (NCT02717611)
- 2022-01-28Results posted on the registry: Acerta Pharma BV, Acalabrutinib + Ibrutinib (NCT02477696)
- 2022-01-19Phase 3 first posted: German CLL Study Group, Obinutuzumab + Venetoclax (NCT05197192)
- 2021-10-29Phase 3 first posted: BeOne Medicines, Zanubrutinib + Rituximab (NCT05100862)
- 2021-09-27Phase 3 first posted: AstraZeneca, Acalabrutinib + Venetoclax (NCT05057494)
- 2021-09-21Phase 3 first posted: Beijing InnoCare Pharma Tech Co., Ltd., Orelabrutinib and R-CHOP + R-CHOP (NCT05051891)
- 2021-08-27Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Bendamustine (NCT05023980)
- 2021-08-18Results posted on the registry: Acerta Pharma BV, Acalabrutinib (Arm A) + Acalabrutinib (Arm B) (NCT02337829)
- 2021-07-16Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Venetoclax (NCT04965493)
- 2021-02-02Results posted on the registry: Washington University School of Medicine, Bendamustine + Rituximab (NCT03623373)
- 2020-12-14Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Idelalisib (NCT04666038)
- 2020-12-10Phase 3 first posted: Loxo Oncology, Inc., Pirtobrutinib + Ibrutinib (NCT04662255)
- 2020-10-29Phase 3 first posted: German CLL Study Group, Ibrutinib + Venetoclax (NCT04608318)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586010)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586023)
- 2020-10-08Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Ibrutinib + Fludarabine (NCT02514083)
- 2020-09-24Phase 3 first posted: Principia Biopharma, a Sanofi Company, Rilzabrutinib + Placebo (NCT04562766)
- 2020-09-10Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Ocrelizumab (NCT04544449)
- 2020-08-28Phase 3 first posted: Acerta Pharma BV, acalabrutinib + placebo (NCT04529772)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision